Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CAPRI-3 cetuximab continuation beyond first-line progression in molecularly selected metastatic colorectal cancer
2024-519322-20-00Phase 3Authorised
- Sponsor
- Gruppo Oncologico dell'Italia Meridionale
- Start
- Jun 2025
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 2
01
Overview
Phase 3, randomised, open-label trial of cetuximab in metastatic colorectal adenocarcinoma (mCRC) and colorectal adenocarcinoma (2 arms), sponsored by Gruppo Oncologico dell'Italia Meridionale. Primary endpoint: Overall response rate. Planned start Jun 2025; status: authorised.
02
Drugs
cetuximab
03
Conditions
metastatic colorectal adenocarcinoma (mCRC)colorectal adenocarcinoma
Beyond the preview
Go deeper on 2024-519322-20-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-519322-20-00.